AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)

B Rini,H Steinfeldt,G Wilding,O Rixe,G Hudes,R Bukowski,M D Michaelson,O Bolte,R Motzer,S D Reich

doi:10.1200/jco.2005.23.16_suppl.4509

AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)

B Rini, H Steinfeldt + Show 8 more

https://doi.org/10.1200/jco.2005.23.16_suppl.4509

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: Jun 1, 2005
Citations: 87

Affiliation: Pfizer (United States), Hochschule Hannover, Cleveland Clinic

#Multi-target Tyrosine Kinase Receptor Inhibitor #Renal Cell Cancer #Von Hippel-Lindau Tumor Suppressor #Clear Cell Renal Carcinoma #Metastatic Renal Cell Cancer #Inactivation Of Tumor Suppressor Gene #Overexpression Of Genes #Multi-target Inhibitor #Inactivation Of Gene #Renal Cancer

Abstract
Full-Text
Similar Papers

Abstract

Listen

4509 Background: Clear cell renal carcinoma (RCC) is characterized by inactivation of the von Hippel-Lindau tumor suppressor gene, which leads to overexpression of hypoxia-regulated genes including...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)